Irinotecan hydrochloride

The main ingredient of this product is irinotecan hydrochloride, and its chemical name is ()-(4S)-4,11-diethyl-4-hydroxy-9-(4-piperidinylpiperidinyl)carbonyl-1H-pyrano-3,4:6,7-indolizine-1,2b-quinoline-3,14-(4H,12H)-dione hydrochloride trihydrate.

1. Neuromuscular blockers: Interactions between irinotecan hydrochloride and neuromuscular blockers cannot be ruled out. Because irinotecan hydrochloride has cholinesterase inhibitor activity, drugs with cholinesterase inhibitory activity can prolong the neuromuscular blocking effect of succinylcholine chloride and can antagonize the neuromuscular blocking effect of non-depolarizing drugs. 2. Antineoplastic drugs: Adverse reactions of this product, such as bone marrow suppression and diarrhea, can be aggravated by other antineoplastic drugs with similar non-responsiveness. 3. Anticonvulsants: Concomitant use of CYP3A-inducing anticonvulsants (such as carbamazepine, phenobarbital or phenytoin) can cause reduced exposure to SN-38. For patients who require anticonvulsant treatment, consideration should be given to starting or switching to non-enzyme-inducing anticonvulsants at least one week before the first use of irinotecan hydrochloride. 4. Ketoconazole: Simultaneous treatment with ketoconazole can cause a significant decrease in the clearance of irinotecan hydrochloride, resulting in increased exposure to its active metabolite SN-38. Ketoconazole should be discontinued at least one week before starting irinotecan hydrochloride treatment, and it should not be administered with irinotecan hydrochloride. 5. St. John's Wort (Hypericum perforatum): Exposure to the active metabolite SN-38 is reduced in patients who are also treated with Hypericum perforatum. Discontinue Hypericum perforatum at least one week before the first use of irinotecan hydrochloride, and it should not be used simultaneously with irinotecan hydrochloride. 6. Atazanavir: Concomitant use of atazanavir, an inhibitor of CYP3A4 and UGTIA1, may increase SN-38 exposure. Physicians should take this into account when using these drugs simultaneously. 7. Dexamethasone: Lymphocytopenia has been reported in patients receiving irinotecan hydrochloride, and dexamethasone may aggravate this condition when used as an antiemetic. However, no serious opportunistic infections have been found, nor have any complications caused by lymphocytopenia been found. Hyperglycemia has been reported in patients receiving this product. This usually occurs in patients with a history of diabetes or impaired glucose tolerance prior to treatment with this drug. The increase in blood sugar in some patients may be caused by receiving dexamethasone. 8. Prochlorperazine: In clinical studies of a single weekly dosing regimen, the incidence of akathisia was higher in patients who were given prochlorperazine on the day of irinotecan hydrochloride treatment (8.5%, 4/47 patients), and lower when the two drugs were not given on the same day (1.3%, 1/80 patients). However, the 8.5% incidence of akathisia is still within the range reported for akathisia when prochlorperazine is used as a pre-chemotherapy drug with other drugs. 9. Laxatives: The use of laxatives while treating with this drug may increase the severity or incidence of diarrhea, but no studies have been conducted in this regard. 10. Diuretics: Due to the potential risk of secondary dehydration after vomiting and/or diarrhea, physicians should avoid using diuretics during irinotecan hydrochloride treatment, and of course, diuretics should not be used during diarrhea or vomiting. Physicians should avoid the use of diuretics during treatment with irinotecan hydrochloride because of the potential risk of dehydration secondary to vomiting and/or diarrhea, and certainly not during diarrhea or vomiting.

The main ingredient of this product is irinotecan hydrochloride, and its chemical name is ()-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinylpiperidine)carbonyl]-1H-pyrano[3,4:6,7]indolizine[1,2b]quinoline-3,14-(4H,12H)-dione hydrochloride trihydrate.

Not yet clear.

The main ingredient of this product is irinotecan hydrochloride, and its chemical name is ()-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinylpiperidine)carbonyl]-1H-pyrano[3,4:6,7]indolizine[1,2b]quinoline-3,14-(4H,12H)-dione hydrochloride trihydrate.

Not yet clear.